Table 2:

Multivariate cox proportional hazard model for overall survival in clinical cohorts

	Univariate analysis			Multivariate analysis
Variable	HR	95%CI	P-value	HR	95%CI	P-value
Tissue cohort (n=199)
Age ≧ 68	0.91	0.63–1.32	0.63
Male	1.09	0.76–1.58	0.64
Pancreatic head cancer	2.37	1.53–3.81	<0.0001	1.66	1.04–2.74	0.03
Tumor size > 30mm	1.4	0.95–2.04	0.08
Poorly differentiated histology	2.37	1.48–3.64	0.0005	1.59	0.98–2.49	0.06
T-Stage ≧3	4	1.50–16.26	0.003	1.82	0.63–7.71	0.29
Lymph node metastasis positive	2.17	1.41–3.45	0.0003	1.22	0.77–2.01	0.41
Distant organ metastasis positive	3.28	1.59–6.03	0.002	3.12	1.49–5.89	0.004
Lymphatic vessel invasion positive	2.58	1.51–4.84	0.0003	1.94	1.07–3.81	0.03
Venous invasion positive	1.09	0.75–1.61	0.65
MiRNA combined signature high risk	2.52	1.74–3.66	<0.0001	2.43	1.65–3.59	<0.0001
Serum cohort (n=51)
Age ≧ 68	1.31	0.67–2.53	0.43
Male	1.11	0.56–2.26	0.77
Pancreatic head cancer	0.6	0.31–1.22	0.15
Tumor size > 30mm	1.06	0.55–2.09	0.85
Poorly differentiated histology	0.49	0.14–1.27	0.15
T-Stage ≧3	1.74	0.73–5.10	0.22
Lymph node metastasis positive	2.87	1.45–5.75	0.003	2.39	0.83–6.93	0.11
Distant organ metastasis positive	9.44	3.89–22.16	<0.0001	7.19	2.51–21.76	0.0003
Lymphatic vessel invasion positive	3.27	1.61–6.91	0.001	1.27	0.44–3.48	0.65
Venous invasion positive	NA	NA	NA
MiRNA combined signature high risk	2.88	1.22–8.45	0.01	4.46	1.73–14.16	0.001

HR, Hazard Ratio; CI, Confidence Interval; NA, Not available. Bold indicates a statistically significant.